Drug Development
With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, “Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets said Tuesday.
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
The new study findings may pave the way for Bristol Myers Squibb to receive additional approval for Breyanzi in a vulnerable patient population.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Synthekine and Bright Peak made announcements on their Series B rounds, while Hawthorne Effect and Owl Peak Labs also secured their funding. Let us take a look.
The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full BLA approval.
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
David S. Knopman and Joel S. Perlmutter both resigned from the committee after the approval of the drug aducanumab.
In a conference call on Wednesday, Biogen CEO Michel Vounatsos outlined the company’s plans for commercial distribution of Aduhelm.
The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.
Pfizer says it expects the U.S. CDC’s ACI to meet in October to recommend the appropriate and safe use of pneumococcal vaccines, including PREVNAR 20, in adults.
Bharat will conduct Phase IV studies to check real-world efficacy against the virus, while Ocugen says Covaxin will be a valuable tool in helping to end the COVID-19 pandemic.